Apricus Biosciences Eyes New Record Lows After FDA Rejection

The FDA cited safety concerns in its latest rejection of APRI's erectile dysfunction cream

Feb 16, 2018 at 8:58 AM
facebook X logo linkedin

Shares of San Diego-based Apricus Biosciences Inc (NASDAQ:APRI) are getting hammered this morning, after the U.S. Food and Drug Administration (FDA) once again declined to approve its Vitaros erectile dysfunction cream. Regulators cited safety concerns regarding an ingredient in the drug known as DDAIP.HCI, and also pointed to "deficiencies related to Chemistry, Manufacturing and Control," per a company statement.

Apricus CEO Richard Pascoe said the company is "disappointed" with the outcome of the FDA review, and expects to provide an update on the drug's future prospects in early March. Vitaros is already widely available outside the U.S. market, including Mexico, Canada, and throughout Europe.

APRI has tanked more than 73% in electronic trading, after settling Thursday's session at $3.19. The pre-market drop has Apricus shares trading south of the $1 mark, and on pace to slice through recent support at their 20-day, 40-day, and 80-day moving averages. In fact, the drug stock is at risk of setting a new all-time low, with the equity hovering just below last May's nadir of $0.86 in electronic action.

Short sellers will likely be pleased with APRI's early bearish momentum. Short interest on the stock ramped up by 13.4% during the past two reporting periods, and now accounts for 7.6% of the stock's available float. Of course, with the shares down so drastically in pre-market trading, short selling is likely to be restricted today -- and if any of these bears decide to take profits, the resulting buying pressure could help APRI find a floor.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI